Abstract
A 57-year-old man with gastrointestinal stromal tumor (GIST) of the stomach with peritoneal dissemination underwent gastrectomy. After surgery, he was treated with 400 mg/day of imatinib, without recurrence, for 26 months. At 26 months, the imatinib dose was reduced because of nausea, and 4 months after the dose reduction, recurrence of GIST was detected, for which surgical resection was performed again. The first surgical specimen had a mutation of exon 11 in the c-kit receptor gene. Intriguingly, the second surgical specimen had a novel mutation of exon 17, in addition to the above-mentioned mutation, in the c-kit receptor gene. Based on the result of molecular analysis, the novel mutation of exon 17, induced by longterm chemotherapy, was judged to have been responsible for the recurrence, which perhaps was triggered by the dose reduction of imatinib.
Article PDF
Similar content being viewed by others
References
S Hirota K Isozaki Y Moriyama K Hashimoto T Nishida S Ishiguro et al. (1998) ArticleTitleGain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577–80 Occurrence Handle9438854 Occurrence Handle1:CAS:528:DyaK1cXotVyhsw%3D%3D Occurrence Handle10.1126/science.279.5350.577
Y Ma S Zeng DD Metcalfe C Akin S Dimitrijevic JH Butterfield et al. (2002) ArticleTitleThe c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors: kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations Blood 99 1741–4 Occurrence Handle11861291 Occurrence Handle1:CAS:528:DC%2BD38XhvFyqurg%3D Occurrence Handle10.1182/blood.V99.5.1741
M Debiec-Rychter J Cools H Dumez R Sciot M Stul N Mentens et al. (2005) ArticleTitleMechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants Gastroenterology 128 270–9 Occurrence Handle15685537 Occurrence Handle1:CAS:528:DC%2BD2MXitVemsL8%3D Occurrence Handle10.1053/j.gastro.2004.11.020
E Tamborini L Bonadiman A Greco V Albertini T Negri A Gronchi et al. (2004) ArticleTitleA new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient Gastroenterology 127 294–9 Occurrence Handle15236194 Occurrence Handle1:CAS:528:DC%2BD2cXmsVShsL8%3D Occurrence Handle10.1053/j.gastro.2004.02.021
S Hirota A Ohashi T Nishida K Isozaki K Kinoshita Y Shinomura et al. (2003) ArticleTitleGain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors Gastroenterology 125 660–7 Occurrence Handle12949711 Occurrence Handle1:CAS:528:DC%2BD3sXnvVSiur8%3D Occurrence Handle10.1016/S0016-5085(03)01046-1
MC Heinrich DJ Griffith BJ Druker CL Wait KA Ott AJ Zigler (2000) ArticleTitleInhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor Blood 96 925–32 Occurrence Handle10910906 Occurrence Handle1:CAS:528:DC%2BD3cXltlKitLw%3D
BJ Druker S Tamura E Buchdunger S Ohno GM Segal S Fanning et al. (1996) ArticleTitleEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 561–6 Occurrence Handle8616716 Occurrence Handle1:CAS:528:DyaK28Xislyhs70%3D Occurrence Handle10.1038/nm0596-561
H Joensuu PJ Roberts M Sarlomo-Rikala LC Andersson P Tervahartiala D Tuveson et al. (2001) ArticleTitleEffect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 1052–6 Occurrence Handle11287975 Occurrence Handle1:STN:280:DC%2BD3M3gvVekuw%3D%3D Occurrence Handle10.1056/NEJM200104053441404
AT van Oosterom I Judson J Verweij S Stroobants E Donato di Paola S Dimitrijevic et al. (2001) ArticleTitleSafety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Lancet 358 1421–3 Occurrence Handle11705489 Occurrence Handle1:CAS:528:DC%2BD3MXot1Ojtb0%3D Occurrence Handle10.1016/S0140-6736(01)06535-7
J Verweij PG Casali J Zalcberg A LeCesne P Reichardt JY Blay et al. (2004) ArticleTitleProgression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 1127–34 Occurrence Handle15451219 Occurrence Handle1:CAS:528:DC%2BD2cXnvVOiu7o%3D Occurrence Handle10.1016/S0140-6736(04)17098-0
MJ Frost PT Ferrao TP Hughes LK Ashman (2002) ArticleTitleJuxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant Mol Cancer Ther 1 1115–24 Occurrence Handle12481435 Occurrence Handle1:CAS:528:DC%2BD3sXmtFamsQ%3D%3D
CR Antonescu P Besmer T Guo K Arkun G Hom B Koryotowski et al. (2005) ArticleTitleAcquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation Clin Cancer Res 11 4182–90 Occurrence Handle15930355 Occurrence Handle1:CAS:528:DC%2BD2MXks1GksLw%3D Occurrence Handle10.1158/1078-0432.CCR-04-2245
JY Blay S Bonvalot P Casali H Choi M Debiec-Richter AP Dei Tos et al. (2005) ArticleTitleConsensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO Ann Oncol 16 566–78 Occurrence Handle15781488 Occurrence Handle10.1093/annonc/mdi127
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Koyama, T., Nimura, H., Kobayashi, K. et al. Recurrent gastrointestinal stromal tumor (GIST) of the stomach associated with a novel c-kit mutation after imatinib treatment. Gastric Cancer 9, 235–239 (2006). https://doi.org/10.1007/s10120-006-0368-5
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10120-006-0368-5